Outcome of Surgery as Part of Palliative Care of Patients with Symptomatic Advanced or Metastatic Extra-Abdominal High-Grade Soft Tissue Sarcoma.
advanced soft tissue sarcoma
palliative plastic surgery
retrospective study
sarcoma resection
Journal
Palliative medicine reports
ISSN: 2689-2820
Titre abrégé: Palliat Med Rep
Pays: United States
ID NLM: 101770666
Informations de publication
Date de publication:
2023
2023
Historique:
accepted:
14
02
2023
entrez:
21
3
2023
pubmed:
22
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
The modern multimodal treatment of malignant tumors has increased disease-specific survival and decreased the burden of tumor-associated complications. The main focus of palliative surgery is not based primarily on quantitative success parameters of tumor response but is instead mainly on the question of quality of life. The current study was conducted to analyze the clinical and oncological outcomes of palliative patients with soft tissue sarcoma. Of 309 patients with extra-abdominal high-grade soft tissue sarcoma treated between August 2012 and December 2014, our retrospective analysis revealed 33 palliative patients for this study. All patients were evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma treatment. The survival analysis was made using the Kaplan-Meier method. The main sarcoma symptoms were pain (27.3%) and ulcerated tumors or shortly before ulceration (24.2%). Thirteen patients (39.4%) were operated on with negative margins, 15 (45.5%) with positive margins, 2 with tumor debulking (6.1%), and 3 patients (9.1%) were treated only with palliative hyperthermic isolated limb perfusion. Ten pedicle flaps were performed after sarcoma resection. The median operation time was 85 minutes (range, 37-216 minutes). The median hospitalization stay was 9.5 days (range, 3-27 days). No patients died during hospitalization. Twelve-month disease-free survival was 48.5% (95% confidence interval: 45.4-51.6). Palliative surgery of metastatic or advanced soft tissue sarcoma can improve the wound care and quality of life. Closed noninfected wounds enable further treatment options, such as chemotherapy, immunotherapy, and radiotherapy. This surgery should be considered during the discussion on interdisciplinary tumor boards.
Sections du résumé
Background
UNASSIGNED
The modern multimodal treatment of malignant tumors has increased disease-specific survival and decreased the burden of tumor-associated complications. The main focus of palliative surgery is not based primarily on quantitative success parameters of tumor response but is instead mainly on the question of quality of life.
Aim
UNASSIGNED
The current study was conducted to analyze the clinical and oncological outcomes of palliative patients with soft tissue sarcoma.
Design
UNASSIGNED
Of 309 patients with extra-abdominal high-grade soft tissue sarcoma treated between August 2012 and December 2014, our retrospective analysis revealed 33 palliative patients for this study. All patients were evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma treatment. The survival analysis was made using the Kaplan-Meier method.
Results
UNASSIGNED
The main sarcoma symptoms were pain (27.3%) and ulcerated tumors or shortly before ulceration (24.2%). Thirteen patients (39.4%) were operated on with negative margins, 15 (45.5%) with positive margins, 2 with tumor debulking (6.1%), and 3 patients (9.1%) were treated only with palliative hyperthermic isolated limb perfusion. Ten pedicle flaps were performed after sarcoma resection. The median operation time was 85 minutes (range, 37-216 minutes). The median hospitalization stay was 9.5 days (range, 3-27 days). No patients died during hospitalization. Twelve-month disease-free survival was 48.5% (95% confidence interval: 45.4-51.6).
Conclusions
UNASSIGNED
Palliative surgery of metastatic or advanced soft tissue sarcoma can improve the wound care and quality of life. Closed noninfected wounds enable further treatment options, such as chemotherapy, immunotherapy, and radiotherapy. This surgery should be considered during the discussion on interdisciplinary tumor boards.
Identifiants
pubmed: 36941924
doi: 10.1089/pmr.2022.0063
pii: 10.1089/pmr.2022.0063
pmc: PMC10024585
doi:
Types de publication
Journal Article
Langues
eng
Pagination
64-70Informations de copyright
© Farhad Farzaliyev et al., 2023; Published by Mary Ann Liebert, Inc.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Plast Reconstr Surg Glob Open. 2021 Mar 15;9(3):e3457
pubmed: 33747689
J Natl Compr Canc Netw. 2018 Feb;16(2):144-152
pubmed: 29439175
BMC Palliat Care. 2014 Jul 31;13:38
pubmed: 25161387
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Ann Surg Oncol. 2002 Jan-Feb;9(1):104-12
pubmed: 11829424
Clin Sarcoma Res. 2016 Jul 11;6:11
pubmed: 27403280
Nurs Clin North Am. 2016 Sep;51(3):513-31
pubmed: 27497023
Cancer. 2008 Apr 1;112(7):1585-91
pubmed: 18278813
Zentralbl Chir. 2015 Apr;140(2):228-34
pubmed: 23696204
Jpn J Clin Oncol. 2021 Jan 1;51(1):78-84
pubmed: 33037437
Handchir Mikrochir Plast Chir. 2016 Dec;48(6):340-345
pubmed: 28033624
Palliat Med. 2015 May;29(5):470-3
pubmed: 25524962
J Palliat Med. 2020 Jun;23(6):848-862
pubmed: 32349622
World J Surg Oncol. 2017 Apr 13;15(1):84
pubmed: 28403880
Front Surg. 2014 Oct 20;1:42
pubmed: 25593966
Surg Oncol Clin N Am. 2004 Jul;13(3):531-41, ix
pubmed: 15236734
Int Orthop. 2017 Dec;41(12):2613-2618
pubmed: 28971269
BMC Palliat Care. 2021 Jan 14;20(1):16
pubmed: 33446180
J Med Case Rep. 2023 Jan 9;17(1):8
pubmed: 36624449